CYP1B1 and prostate carcinoma: Although it is controversial [33, 34], one of the CYP1B1 polymorphic variants, Leu432Val, which may increase enzymatic activity, is associated with low response to taxane in breast cancer [12] and poor prognosis in docetaxel-treated prostate cancer patients [13, 35].